Jade Biosciences, Inc. (NASDAQ:JBIO) reported interim Phase 1 results for JADE101 in immunoglobulin A nephropathy (IgAN), showing substantial and sustained reductions in immunoglobulin A (IgA), a favorable safety profile, and pharmacokinetic data that could support a convenient dosing schedule.
According to the interim analysis, a single 700 mg dose of JADE101 reduced IgA levels by about 70% from baseline, with the effect sustained through 12 weeks. The company said the reductions appeared deeper, faster, and more durable than those reported for first-generation anti-APRIL therapies and dual APRIL/BAFF inhibitors.
Modeling data suggest a regimen consisting of a single 700 mg induction dose followed by 350 mg subcutaneous maintenance injections every 12 weeks could maintain IgA reductions above 70% at steady state, requiring just four injections per year.
Phase 2 Trial Continues As Phase 3 Plans Take Shape
Jade Biosciences is currently conducting the JUNIPER Phase 2 trial in approximately 30 participants with IgAN. The study is evaluating a 700 mg induction dose followed by 350 mg maintenance doses administered either every eight weeks or every 12 weeks.
The company expects interim clinical data from JUNIPER in 2027 and plans to begin a registrational Phase 3 trial in the first half of 2027.
William Blair notes that the stock weakness is due to investors questioning the lack of quantitative disclosures around Anti-Drug Antibodies (ADAs).
Analyst Matt Phipps notes that in follow-up with management, it emphasized that there has been no impact of ADAs on the pharmacokinetics of JADE101 or subsequent pharmacodynamic markers, and any ADAs detected with an ultrahigh-sensitive assay have been late-onset and low-titer.
“Overall, we believe the profile of JADE101 is very strong, and management's execution has accelerated our previously estimated development timelines, pulling forward our expected FDA approval by at least six to nine months,” William Blair wrote on Monday.
Image via Shutterstock
Login to comment